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Abstract: We validate specific binding activity of a fluorescence-labeled 
peptide to colorectal dysplasia in living mice using a miniature, flexible, 
fiber  microendoscope  that  passes  through  the  instrument  channel  of  an 
endoscope. The microendoscope delivers excitation light at 473 nm through 
a fiber-optic bundle with outer diameter of 680 µm to collect en face images 
at 10 Hz with 4 µm lateral resolution. We applied the FITC-labeled peptide 
QPIHPNNM  topically  to  colonic  mucosa  in  genetically  engineered  mice 
that  spontaneously  develop  adenomas.  More  than  two-fold  greater 
fluorescence intensity was measured from adenomas compared to adjacent 
normal-appearing  mucosa.  Images  of  adenomas  showed  irregular 
morphology characteristic of dysplasia. 
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1. Introduction 
Although use of colonoscopy for early detection of colorectal cancer has led to a decreased 
incidence over the past two decades, this disease is still one of the most common cancers in 
the U.S [1]. Traditional white-light endoscopy relies on gross architectural changes and is not 
sensitive to molecular changes that develop as normal colonic epithelium transforms into a 
pre-malignant condition (dysplasia) prior to evolving into adenocarcinoma [2]. Furthermore, 
white-light  endoscopy  cannot  distinguish  between  dysplasia  and  hyperplasia,  a  benign 
epithelial proliferation. Intra-vital microscopes can be used to validate the unique expression 
pattern of molecular targets in diseased tissues with use of highly specific exogenous probes 
[3,4]. Additionally, these probes can be used to guide therapy [5], stratify risk, and localize 
margins, aiding the clinician’s decision-making ability on a patient-to-patient basis [6]. 
Genetically  engineered  small  animal  models  can  be  used  to  study  the  molecular 
progression  of  cancer  that  develops  spontaneously  over  time  [7].  While  non-invasive 
techniques such as PET, bioluminescence, and MRI can serially image an animal, they cannot 
provide cellular detail in real time due to limitations in spatial resolution [8]. On the other 
hand, conventional intra-vital microscopes can achieve sub-cellular resolution, but their large 
dimensions in general require either an invasive incision or use of optical windows, limiting 
serial  studies  or  working  distance,  respectively  [9].  We  have  recently  demonstrated  a 
miniature  microendoscope that can directly and repetitively image  the epithelium of deep 
tissues with sub-cellular resolution in living mice [10]. 
Our  laboratory  has  previously  discovered  a  fluorescent  peptide  probe  that  specifically 
binds to murine colorectal dysplasia. This peptide (QPIHPNNM) was FITC-tagged and used 
to localize colonic dysplasia in vivo on wide-field fluorescence endoscopy [11]. Here, we aim 
to demonstrate the use of microendoscopy to validate selective binding by this peptide on a 
sub-cellular scale. This microendoscope is sufficiently small to pass through the instrument 
channel of the endoscope for direct placement onto the mucosal surface. Its fast frame rate can 
overcome motion artifact from the live animal introduced by organ peristalsis, heart beating, 
and breathing. We use this instrument to validate specific binding activity of QPIHPNNM to 
dysplasia  in  comparison  to  adjacent  normal  mucosa  and  to  hyperplasia.  Additionally,  we 
validate the in vivo images with conventional confocal images collected with a bench top 
instrument.  This  study  demonstrates  a  rigorous  methodology  for  the  validation  of  novel 
molecular probes being developed as a targeting agent for disease in hollow organs. 
2. Methods 
2.1. System design 
A schematic of the imaging system is shown in Fig. 1. A diode pumped solid state laser (CNI 
MBL-III-473,  Changchun,  China)  produces  emission  centered  at  473  nm.  The  power  is 
adjusted to achieve 1 mW at the distal end of the microendoscope. The beam is collimated by 
an aspheric lens (L1, f = 18 mm), reflected by a 495 nm dichroic beamsplitter (Semrock 
FF495-Di02-25x36), and focused into a coherent fiber bundle (Sumitomo IGN-06/17, Osaka, 
Japan) by an infinity corrected objective lens (Olympus UIS2 PLN 20X, Tokyo, Japan). The 
bundle has ~17,000 fibers with core-to-core spacing of ~4 µm. The fluorescence image is 
magnified by the objective, passes through the dichroic, and is focused by a condenser lens 
(L2, f = 100 mm) onto a CCD camera (Hamamatsu Orca R2, Hamamatsu City, Japan). A 500 
nm long-pass filter (LPF, Semrock BLP01-488R-25) blocks the reflected excitation light. 
The 680 µm outer diameter fiber bundle is sufficiently small to pass through the 3 Fr (~1 
mm diameter) instrument channel of the rigid endoscope (Karl Storz, Tuttlingen, Germany) 
(Fig. 1, inset). This endoscope has outer dimensions of 2.7 mm x 3.5 mm, and is used to 
localize the adenomas with white light illumination [12]. The instrument channel is also used  
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Fig. 1. Schematic. Excitation from the laser diode at 473 nm is collimated by an asphere (L1), 
reflected by a dichroic beamsplitter, and focused into a 680 µm (O.D.) coherent fiber bundle. 
Fluorescence is transmitted to the CCD. The bundle is sufficiently small in dimension to pass 
through the instrument channel of a small animal endoscope (inset). 
to administer the peptides and to provide insufflation to distend the lumen of the colon for 
imaging. 
2.2. Animal models 
All animal experiments were approved by the University of Michigan Committee for Use and 
Care of Animals (UCUCA). We used the CPC;Apc mouse model of spontaneous colorectal 
dysplasia,  developed  by  Hinoi  et  al.  [13],  to  validate  the  peptide  probe. APC  is  a  tumor 
suppressor gene that is mutated in over 75% in human colorectal tumors [14]. In this mouse, 
the Apc gene locus is deleted by a Cre recombinase, resulting in the development of adenomas 
in the distal colon and rectum beginning at 10 weeks of age. Cre( + ) mice develop adenomas; 
Cre(-) mice and the Kras mouse model of colorectal hyperplasia are used as controls [15]. 
The CPC;Apc mice ranged in age from 5 to 6 months, and the Kras mice from 1 to 2 months. 
2.3. In vivo microendoscopy 
The target (QPIHPNNM) and control (GGGAGGGA) peptides were synthesized with Fmoc 
chemistry,  conjugated  with  5′-fluorescein  isothiocyanate  (FITC)  via  amino  hexanoic  acid 
linker, and purified with HPLC, as previously described [11]. These peptides were diluted to 
100 µM in 1X phosphate buffered saline (PBS). Mice were placed prone and anesthetized 
with  isoflurane.  After  rinsing  the  colon  with  water  to  remove  debris  and  mucous, 
approximately 1 mL of the peptide solution was administered intra-luminally to the mucosa. 
The peptide was allowed to incubate for 5 minutes, and subsequently, the unbound peptide 
was rinsed 3X with water. The endoscope was used to localize adenomas with white light 
illumination. The microendoscope was then passed through the instrument channel, and the 
distal end  was positioned  for complete contact  with the  mucosal surface. The  white  light 
source was turned off, and fluorescence images were collected with an exposure of 100 ms 
(frame rate of 10 Hz). All microendoscopy images are presented as single frames extracted 
from video recordings. A representative video is provided for target peptide on the surface of 
an adenoma. 
The target and control peptides are individually applied to the mucosa of Cre( + ) mice (n 
= 6 and n = 4, respectively). Microendoscopic images were acquired from the surface of the 
one adenoma and the adjacent normal-appearing mucosa in each mouse. The specificity of 
QPIHPNNM for dysplasia was further validated by applying the peptide to normal mucosa of 
Cre(-) mice (n = 1) that do not develop adenomas, and to hyperplastic mucosa of Kras mice (n 
= 2). Autofluorescence images were taken from Cre( + ) mice (n = 1) and Kras mice (n = 2) 
for purposes of comparison. 
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To validate the in vivo images collected with the microendoscope, we collected fluorescence 
images  from  freshly  excised  tissues  with  a  bench  top  confocal  microscope  (Olympus 
FluoView  500,  Tokyo,  Japan).  The  mice  were  euthanized,  and  a  pair  of  adenomas  were 
excised (n = 3 mice, n = 5 adenoma pairs) from each mouse. Adenomas were incubated in 100 
µM solution of either QPIHPNNM or GGGAGGGA for 5 minutes, and then rinsed 3X with 
PBS. The adenomas were then placed with the mucosal surface facing the objective lens and 
imaged using 488 nm excitation. 
2.5. Data analysis 
Microendoscopic images were collected at 12-bit resolution (0 – 4095 AU). All images were 
acquired as videos of 2 second duration, and contained 21 frames. Criteria for frame selection 
include: 1) entire image being in focus (flat contact of microendoscope with the mucosal 
surface), and 2) no saturated pixels. The mean fluorescence intensity ± one standard deviation 
error was then determined for each image. Those mean intensities were then averaged for all 
adenomas and normal tissues from each mouse. Additionally, we measured autofluorescence 
from the adenomas and hyperplastic mucosa. Statistical significance was determined by 2-
sample t-test, α<0.05 (Minitab 16, State College, PA, USA). 
The  target-to-background  ratios  (T/B)  of  peptide  binding  to  adenomas  versus  normal-
appearing adjacent mucosa for each peptide were calculated by dividing the average mean 
intensity from adenomas by that from normal mucosa for each mouse. The results from all 
mice were then averaged to determine the overall T/B for each peptide. 
3. Results 
3.1. System design 
The microendoscope achieves a field-of-view with a diameter of 540 µm and has a lateral 
resolution of 4 µm, verified by a standard (USAF) resolution target. 
3.2. In vivo microendoscopy 
The  microendoscopy  images  revealed  that  the  target  peptide  QPIHPNNM  demonstrates 
greater  binding  to  adenomas  than  to  the  normal-appearing  surrounding  mucosa,  as 
demonstrated by the greater fluorescence intensity (Fig. 2a-b). In addition, the binding pattern 
reflects  cellular  features  specific  to  the  mucosal  surface.  In  contrast,  the  control  peptide 
(GGGAGGGA) shows minimal fluorescence and does not reveal cellular features for either 
dysplastic  or  normal  mucosa  (Fig.  2c-d).  Furthermore,  QPIHPNNM  shows  minimal 
fluorescence signal from the normal mucosa, demonstrating little non-specific binding (Fig. 
2e).  The  autofluorescence  signal  from  adenomas  is  also  minimal  (Fig.  2f).  Fluorescence 
intensity from QPIHPNNM applied to the hyperplastic mucosa of the Kras mouse model (Fig. 
2g) is comparable to the autofluorescence signal from the same tissue (Fig. 2h). The full 
acquired video for Fig. 2a is provided (Media 1). 
The mean fluorescence intensity from adenomas averaged across all mice, 773 ± 99, is 
significantly  higher  than  that  from  the  normal-appearing  surrounding  mucosa,  384  ±  93, 
(p<0.001). The T/B of QPIHPNNM from adenomas to the adjacent normal mucosa, 2.11 ± 
0.61, is significantly higher than that of the control peptide GGGAGGGA, 1.16 ± 0.10 (p = 
0.016) (Fig. 3a). The autofluorescence, measured from adenomas on the Cre( + ) mice and 
hyperplasia on the Kras mice, are 297 ± 48 and 471 ± 36, respectively. After subtraction of 
autofluorescence,  the  mean  intensity  from  QPIHPNNM  applied  to  adenomas,  normal-
surrounding mucosa of Cre( + ) mice, hyperplasia, and normal mucosa of Cre(-) mice are 476 
± 110, 87 ± 105, 46 ± 64, and 81 ± 62, respectively (Fig. 3b), resulting in a T/B for dysplasia 
to normal (Cre + ), hyperplasia, and normal (Cre-) of 5.5, 10.3, and 5.9, respectively. 
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Fig. 2. In vivo microendoscopy images. QPIHPNNM applied to the surface of a) an adenoma 
(Media 1) and b) normal-appearing adjacent mucosa. GGGAGGGA (control peptide) applied 
to the surface of c) an adenoma and d) normal-appearing adjacent mucosa. e) QPIHPNNM 
applied to normal colonic mucosa in Cre(-) mice. f) Autofluorescence from adenoma in Cre(+) 
mice. g) QPIHPNNM applied to hyperplastic mucosa of Kras mouse. h) Autofluorescence 
signal from Kras mouse. Scale bar = 100 µm. 
 
Fig. 3. Quantification of average fluorescence intensities. (a) Boxplot of T/B of peptides from 
adenomas to adjacent normal mucosa. T/B of QPIHPNNM is significantly higher than that of 
GGGAGGGA. Lower, middle, and top lines of boxes indicate lower quartile, median, and 
upper quartile, respectively. Whiskers indicate minima and maxima, and crosshairs indicate 
means. (b) Mean fluorescence intensity of QPIHPNNM, after autofluorescence subtraction. 
Fluorescence signal from dysplasia is at least five-fold greater than from all other tissues. 
3.3. Comparison of in vivo microendoscopy to ex vivo confocal microscopy 
Fluorescence  images  of  freshly  excised  adenomas  incubated  with  QPIHPNNM  and 
GGGAGGGA collected with a bench top confocal microscope are shown in Fig. 4. The image 
of QPIHPNNM (Fig. 4a) demonstrates binding pattern of the target peptide to single epithelial 
cells,  representing  similar  morphological  features  to  that  seen  on  microendoscopy. 
Comparatively, the ex vivo confocal microscopy (Fig. 4b) image shows minimal fluorescence 
signal  and  no  resolvable  cellular  features  using  the  GGGAGGGA  (control)  peptide. 
Hematoxylin and eosin stained biopsy specimens of adenomas reveal enlarged nuclei and 
distorted crypts characteristic of dysplasia (Fig. 4c), as previously shown [11]. 
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Fig.  4.  Ex  vivo  confocal  microscopy  images.  (a)  QPIHPNNM  shows  binding  to  single 
epithelial cells (arrow). (b) Minimal binding was revealed on using the GGGAGGGA peptide. 
(c) Histology confirms dysplastic crypts in adenoma biopsy specimens. Scale bar = 20 µm. 
4. Discussion 
Here, we demonstrate a methodology for validation of selective binding of a fluorescence-
labeled  peptide  to  colonic  dysplasia  with  sub-cellular  resolution  in  living  mice  using  a 
microendoscope.  The  experiments  confirm  specific  binding  activity  of  the  target  peptide 
(QPIHPNNM) to dysplasia in comparison to hyperplastic and normal colonic mucosa and to 
the control peptide (GGGAGGGA) on a microscopic scale. The T/B of both the target and 
control peptides for adenomas and to adjacent normal mucosa on microendoscopy, shown in 
Fig. 3a, are consistent  with those found for the same peptides on  wide-field fluorescence 
endoscopy  [11].  This  result  is  expected  because  the  microendoscope  images  the  mucosal 
surface,  as  does  the  wide-field  fluorescence  endoscope.  Moreover,  The  T/B  of  the  target 
peptide  improves  with  subtraction  of  mucosal  autofluorescence.  This  integrated  strategy 
combines the use of a wide-area endoscope to guide placement of the microendoscope to 
achieve both a large field of view for localization and sub-cellular resolution for validation in 
real time. 
In addition, a comparison of the microendoscope to bench top confocal images of peptide 
binding to adenomas reveals similar spatial patterns. This result demonstrates the ability of the 
microendoscope to acquire sub-cellular images in living mice, in real time, allowing for the 
study of molecular expression patterns of pre-malignant epithelial cells in vivo, using each 
animal as its own control. This enabling technology can greatly reduce the number, hence 
cost, of animals needed to perform validation studies with robust statistics. In addition, the 
process of euthanizing animals and excising tissue may introduce artifacts in the data. Given 
the  time  needed  to  dissect  the  animal,  resect  the  specimen,  and  bring  the  tissue  to  the 
microscope, the fluorescent probes may undergo enzymatic degradation or photobleaching, 
and  the  cells  may  undergo  apoptosis  or  desiccation.  Moreover,  surgical  incisions  may 
introduce trauma, hypoxia, and bleeding that can alter the molecular expression patterns. 
5. Conclusion 
These  results  demonstrate  a  rigorous  methodology  for  multi-scale  validation  of  a  novel 
targeting agent being developed to localize disease that can be generalized to hollow organs. 
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